PMID- 30105657 OWN - NLM STAT- MEDLINE DCOM- 20191021 LR - 20220216 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 35 IP - 9 DP - 2018 Sep TI - Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study. PG - 1400-1410 LID - 10.1007/s12325-018-0762-5 [doi] AB - INTRODUCTION: Invasive fungal infections (IFIs) are a significant health problem in immunocompromised patients, resulting in substantial morbidity, mortality, and healthcare costs. Micafungin is a broad-spectrum echinocandin with activity against Candida and Aspergillus spp. This was a multicenter, non-comparative, retrospective observational study that evaluated the effectiveness and tolerability of intravenously administered micafungin for treating IFIs caused by Candida and Aspergillus spp. METHODS: Adult patients in China who had received at least one dose of intravenously administered micafungin were eligible. Retrospective data (May 2008-April 2015) were extracted from patients' medical files and recorded using electronic data capture. The primary endpoint was overall success rate (patients with complete or partial response). Subgroup analyses determined effectiveness according to diagnostic certainty, fungal species, type of IFI, duration of micafungin treatment, and daily dose of micafungin. Tolerability, including the incidence of adverse events (AEs), was also assessed. RESULTS: Overall, 2555 patients who received at least one dose of micafungin were identified. The mean duration of treatment and mean daily dose were 10.2 days and 133.0 mg, respectively. The overall success rate was 60.8%; this was significantly higher in patients who received treatment for at least 1 week (range 67.9-71.6% [mean 69.2%]) compared with less than 1 week (47.8%; P < 0.0001), and those who received 50-100 mg (65.7%) compared with other daily doses (range 42.9-60.1% [mean 59.0%]; P = 0.0011). Success rates in Candida- and Aspergillus-infected patients were similar (61.9% and 56.8%, respectively). AEs and adverse drug reactions were observed in 36.2% and 4.5% of patients, respectively. The majority of AEs were mild, while discontinuation due to AEs was low (2.3%). CONCLUSION: Micafungin is effective and well tolerated for the treatment of patients with IFIs in China, as demonstrated in Candida- and Aspergillus-infected adults. Subgroup analyses highlighted the potential benefits of treating IFIs with micafungin for a minimum of 1 week. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02678598. FUNDING: Astellas Pharma Inc. FAU - Zheng, Xiaoyun AU - Zheng X AD - Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fujian, China. FAU - Huang, Xiaobo AU - Huang X AD - Sichuan Provincial Peoples' Hospital, Sichuan, China. FAU - Luo, Jianmin AU - Luo J AD - The Second Hospital of Hebei Medical University, Hebei, China. FAU - Li, Juan AU - Li J AD - The First Affiliated Hospital, Sun Yat-sen University, Guangdong, China. FAU - Li, Wei AU - Li W AD - The First Hospital of Jilin University, Jilin, China. FAU - Liu, Qifa AU - Liu Q AD - Nanfang Hospital, Guangdong, China. FAU - Niu, Ting AU - Niu T AD - West China Hospital of Sichuan University, Sichuan, China. FAU - Wang, Xiaodong AU - Wang X AD - Sichuan Provincial Peoples' Hospital, Sichuan, China. FAU - Zhou, Jianfeng AU - Zhou J AD - Tongji Medical College Huazhong University of Science and Technology, Hubei, China. FAU - Zhang, Xi AU - Zhang X AD - XinQiao Hospital, Third Military Medical University, Chongqing, China. FAU - Hu, Jianda AU - Hu J AD - Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fujian, China. drjiandahu@163.com. FAU - Liu, Kaiyan AU - Liu K AD - Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China. liukaiyan@medmail.com.cn. LA - eng SI - ClinicalTrials.gov/NCT02678598 SI - figshare/10.6084/m9.figshare.6865253 PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20180813 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 RN - 0 (Antifungal Agents) RN - R10H71BSWG (Micafungin) MH - Adult MH - Aged MH - Antifungal Agents/administration & dosage/adverse effects/*therapeutic use MH - China MH - Female MH - Humans MH - Incidence MH - Infusions, Intravenous MH - Invasive Fungal Infections/*drug therapy MH - Male MH - Micafungin/administration & dosage/adverse effects/*therapeutic use MH - Middle Aged MH - Retrospective Studies PMC - PMC6133133 OTO - NOTNLM OT - Aspergillus OT - Candida OT - Invasive fungal infections OT - Micafungin OT - Real-world data OT - Retrospective study EDAT- 2018/08/15 06:00 MHDA- 2019/10/23 06:00 PMCR- 2018/08/13 CRDT- 2018/08/15 06:00 PHST- 2018/03/13 00:00 [received] PHST- 2018/08/15 06:00 [pubmed] PHST- 2019/10/23 06:00 [medline] PHST- 2018/08/15 06:00 [entrez] PHST- 2018/08/13 00:00 [pmc-release] AID - 10.1007/s12325-018-0762-5 [pii] AID - 762 [pii] AID - 10.1007/s12325-018-0762-5 [doi] PST - ppublish SO - Adv Ther. 2018 Sep;35(9):1400-1410. doi: 10.1007/s12325-018-0762-5. Epub 2018 Aug 13.